Compare · CCCC vs KYMR
CCCC vs KYMR
Side-by-side comparison of C4 Therapeutics Inc. (CCCC) and Kymera Therapeutics Inc. (KYMR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CCCC and KYMR operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- KYMR is the larger of the two at $9.11B, about 21.3x CCCC ($427.9M).
- Over the past year, CCCC is up 71.6% and KYMR is up 174.9% - KYMR leads by 103.4 points.
- KYMR has been more active in the news (9 items in the past 4 weeks vs 4 for CCCC).
- KYMR has more recent analyst coverage (25 ratings vs 22 for CCCC).
- Company
- C4 Therapeutics Inc.
- Kymera Therapeutics Inc.
- Price
- $3.86+6.78%
- $109.65+0.98%
- Market cap
- $427.9M
- $9.11B
- 1M return
- -1.40%
- -0.71%
- 1Y return
- +71.56%
- +174.95%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 4
- 9
- Recent ratings
- 22
- 25
C4 Therapeutics Inc.
C4 Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.; Biogen, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics Inc.
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Latest CCCC
- SEC Form 10-Q filed by C4 Therapeutics Inc.
- C4 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Chief Medical Officer Reyno Leonard converted options into 15,325 shares and covered exercise/tax liability with 7,397 shares, increasing direct ownership by 2% to 372,406 units (SEC Form 4) (for tax liability)
- Director Grogan Donna Roy was granted 3,341 shares, increasing direct ownership by 5% to 74,853 units (SEC Form 4)
- Director Anderson Kenneth Carl was granted 2,650 shares, increasing direct ownership by 4% to 71,950 units (SEC Form 4)
- SEC Form 4 filed by Director Hughes Owen
- SEC Form 4 filed by Director Hoerter Steven L.
- SEC Form 4 filed by Director Koppikar Utpal
Latest KYMR
- SEC Form 10-Q filed by Kymera Therapeutics Inc.
- Kymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
- Deutsche Bank initiated coverage on Kymera Therapeutics with a new price target
- Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
- Chief Medical Officer Rooney Terence was granted 38,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Rooney Terence
- Kymera Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
- Chief Executive Officer Mainolfi Nello exercised 50,000 shares at a strike of $2.08 and sold $5,950,000 worth of shares (50,000 units at $119.00) as part of a pre-agreed trading plan (SEC Form 4)